Abstract
A major problem in vascularized pancreas transplantation is the lack of reliable methods for the early diagnosis and effective treatment of allograft rejection. Over a 2-year period, 54 rejection episodes occurred in 31 patients (13 isolated pancreas, 18 simultaneous pancreas-kidney recipients) with pancreaticoduodenocystostomy. A total of 253 radionuclide pancreas examinations were performed (mean 8.4 per patient) utilizing 99mtechnetium-DTPA. Computer analysis generated a quantitative measure of blood flow to the allograft caused the technetium index (TI). Rejection episodes were characterized as isolated pancreas (22), combined pancreas-kidney (16), or isolated renal (16) allograft rejection in combined engraftments. The majority of rejection episodes occurred early (within 3 months of transplant, N=47) and were more responsive than late rejection to anti-rejection therapy (89.4% vs 42.9%, P=0.01). Mean urinary amylase (UA) levels and TI during normal allograft function were 29,398 U/l and 0.55%, while levels heralding rejection were 6,528 U/l and 0.40%, respectively (P<0.05). The treatment of rejection based upon renal dysfunction or combined renal and pancreas dysfunction resulted in significantly higher graft salvage with a lower incidence of hyperglycemia when compared to isolated pancreas allograft rejection. Of the 11 patients who developed hyperglycemia, 8 (72.7%) ultimately lost their pancreas grafts (P<0.001). Following therapy, a TI above 0.3% was associated with 97.4% graft survival, while levels below 0.3% resulted in a 70% rate of graft loss (P<0.001). Similarly, pancreas allografts with a UA above 10,000 U/l had 91.1% functional survival, while levels below 10,000 U/l resulted in a 66.7% rate of graft loss (P<0.001). Overall, reversal of rejection occurred in 83.3% of cases, with 9 grafts lost due to rejection at a mean of 4.7 months post-transplant. Therapy with ALG or OKT3 was more effective in reversing allograft rejection than pulsed corticosteroids alone (68.8% vs 47.9%, P=0.05). Patient and pancreas allograft survival is 96.8% and 67.7%, respectively, after a mean follow-up interval of 14.9 months. Monitoring pancreas allograft function by UA, TI, and renal function (in simultaneous transplants) allows for the timely diagnosis and successful treatment of pancreas allograft rejection.
Similar content being viewed by others
References
Baumgartner D, Largiadèr F, Uhlschmid G, Binswanger U (1983) Rejection episodes in recipients of simultaneous pancreas and kidney transplants. Transplant Proc 15: 1330–1331
Borgstrom A, Marks WH, Dafoe DC, Campbell DA Jr, Turcotte JG (1986) Immunoreactive anionic and cationic trypsins in serum after experimental porcine pancreatic transplantation. Surgery 100: 841–849
Corry RJ, Nghiem DD, Schulak JA, Beutel WD, Gonwa TA (1986) Surgical treatment of diabetic nephropathy with simultaneous pancreatic, duodenal and renal transplantation. Surg Gynecol Obstet 162: 547–555
Crass JR, Feinberg SB, Sutherland DER, Loken M, Gedgaudas EG (1982) Radiology of the human segmental pancreatic transplant. Gastrointest Radiol 7: 153–158
Dubernard JM, Traeger J, Touraine JL, Betuel H, Malik MC (1980) Rejection of human pancreatic allografts. Transplant Proc 12: 103–106
Florack G, Sutherland DER, Sibley RK, Najarian JS, Squifflet JP (1985) Combined kidney and segmental pancreas allotransplantation in dogs. Transplant Proc 17: 374–377
Gotoh M, Monden M, Motoki Y, Sakane O, Shima K, Okamura J (1984) Early detection of rejection in the allografted pancreas. Transplant Proc 16: 781–782
Groth CG, Lundgren G, Arner P, Cellste H, Hardstedt C, Lewander R, Ostman J (1976) Rejection of isolated pancreatic allografts in patients with diabetes. Surg Gynecol Obstet 143: 933–940
Grundfest-Bronitowski S, Novick A (1986) Pancreas transplantation — 1985. Transplant Proc [Suppl 2] 18: 31–39
Hahn D, Bull U, Land W (1983) Pancreatic grafts-nuclear perfusion imaging to detect vascular complications and rejection crises. Horm Metab Res [Suppl] 13: 78
Jamieson NV, McMaster P, Wraight EP, Evans DB, Calne RY (1980) Radionuclide imaging in pancreatic transplantation. Nucl Med Commun 1: 291
Land W, Illner WD, Abendroth D, Landgraf R (1984) Experience with 13 segmental pancreas transplants in cyclosporine-treated diabetic patients using ethibloc for duct obliteration (surgical aspects). Transplant Proc 16: 729–732
Munda R, Tom WW, First MR, Gartsid P, Alexander JW (1987) Pancreatic allograft exocrine urinary tract diversion: pathophysiology. Transplantation 43: 95–99
Nghiem DD, Gonwa TA, Corry RJ (1987) Metabolic effects of urinary diversion of exocrine secretions in pancreatic transplantation. Transplantation 43: 70–73
Perlman SB, Deierhoi MH, Wilson MA, Rowe B, Sollinger HW (1986) Noninvasive evaluation of pancreas allografts. J Nucl Med 27: 909
Powell CS, Lindsey NJ, Nolan MS, Wiley KN, Boyle PF, Harold A (1987) The value of urinary amylase as a marker of early pancreatic allograft rejection. Transplantation 43: 921–923
Prieto M, Sutherland DER, Fernández-Cruz L, Heil J, Najarian JS (1987) Experimental and clinical experience with urine amylase monitoring for early diagnosis of rejection in pancreas transplantation. Transplantation 43: 73–79
Schroeder TJ, Weiskittel P, Bailey D, Melvin DB, Munda R, Clardy CW, Balisteri WF, Penn I, Fidler JP, Alexander JW, First MR (1988) Clinical efficacy and side effects of Orthoclone OKT3 in renal, pancreatic, hepatic, and cardiac transplantation. Transplantation (in press)
Schulak JA, Drevyanko TF (1985) Experimental pancreas allograft rejection: correlation between histologic and functional rejection and the efficacy of anti-rejection therapy. Surgery 98: 330–336
Sibley RK, Mukai K (1983) Pathological features in 29 segmental pancreas transplants in 27 patients. Lab Invest 48: 78a
Simeone JF, Wittenberg J, Ferrucci JT (1980) Modern concepts of imaging of the pancreas. Invest Radiol 15: 6
Sollinger HW, Cook K, Kamps D, Glass NR, Belzer FO (1984) Clinical and experimental experience with pancreaticocystostomy for exocrine pancreatic drainage in pancreas transplantation. Transplant Proc 16: 741–751
Sollinger HW, Stratta RJ, Kalayoglu M, Pirsch JD, Belzer FO (1987) Pancreas transplantation with pancreaticocystostomy and quadruple immunosuppression. Surgery 102: 674–679
Starzl TE, Iwatsuki S, Shaw BW, Greene DA, Van Thiel DH, Nalesnik MA, Nusbacher J, Diliz-Pere H, Hakala TR (1984) Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet 159: 265–272
Sutherland DER, Moudry KC (1987) Pancreas transplant registry report — 1986. Clin Transplant 1: 3–17
Sutherland DER, Goetz FC, Najarian JS (1984) One hundred pancreas transplants at a single institution. Ann Surg 200: 414–440
Sutherland DER, Goetz FC, Kendall DM, Najarian JS (1985) One institution's experience with pancreas transplantation. West J Med 143: 838–844
Thistlethwaite JR Jr, Cosimi AB, Delmonico FL, Rubin RH, Tolkoff-Rubin N, Nelson PW, Fang L, Russell PS (1984) Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation 38: 695–701
Thomas F, Bogey W, Castellani W, Khazanie P, Tysor M, Thomas J (1988) Diagnosis of pancreatic allograft rejection by measurement of urinary radioimmunoreactive insulin. Transplantation (in press)
Traeber J, Dubernard JM, Piatti PM, Bosie E, Gebet A, ElYafi S, Betuel H, Secchi A, Touraine JL, Pozza G (1984) Clinical aspects of pancreatic rejection in pancreatic and pancreaticorenal allotransplants. Transplant Proc 16: 718–719
Tyden G, Lundgren G, Gunnarsson R, Ostman J, Groth CG (1984) Laboratory findings during rejection of segmental pancreatic allografts. Transplant Proc 16: 715–717
Tyden G, Lundgren G, Ost L, Gunnarsson R, Ostman J, Groth CG (1986) Are pancreatic grafts prone to rejection? Transplant Proc 17: 27–29
Author information
Authors and Affiliations
About this article
Cite this article
Stratta, R.J., Sollinger, H.W., Perlman, S.B. et al. Early diagnosis and treatment of pancreas allograft rejection. Transplant Int 1, 6–12 (1988). https://doi.org/10.1007/BF00337842
Issue Date:
DOI: https://doi.org/10.1007/BF00337842